KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Depreciation & Amortization (CF) (2020 - 2026)

AbCellera Biologics filings provide 7 years of Depreciation & Amortization (CF) readings, the most recent being $5.9 million for Q1 2026.

  • Quarterly Depreciation & Amortization (CF) rose 34.23% to $5.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $19.8 million through Mar 2026, up 44.95% year-over-year, with the annual reading at $18.4 million for FY2025, 47.2% up from the prior year.
  • Depreciation & Amortization (CF) hit $5.9 million in Q1 2026 for AbCellera Biologics, up from $5.1 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $5.9 million in Q1 2026 and bottomed at $1.4 million in Q1 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $3.4 million, with a median of $3.2 million recorded in 2024.
  • The largest annual shift saw Depreciation & Amortization (CF) plummeted 46.53% in 2024 before it skyrocketed 147.21% in 2025.
  • AbCellera Biologics' Depreciation & Amortization (CF) stood at $2.7 million in 2022, then surged by 40.75% to $3.9 million in 2023, then plummeted by 46.53% to $2.1 million in 2024, then skyrocketed by 147.21% to $5.1 million in 2025, then rose by 16.04% to $5.9 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Depreciation & Amortization (CF) are $5.9 million (Q1 2026), $5.1 million (Q4 2025), and $4.3 million (Q3 2025).